Bayesian cost-effectiveness analysis from clinical trial data

被引:70
|
作者
O'Hagan, A [1 ]
Stevens, JW
Montmartin, J
机构
[1] Univ Sheffield, Dept Probabil & Stat, Sheffield S3 7RH, S Yorkshire, England
[2] Astra Zeneca, Stat & Data Management Dept, Loughborough LE11 7RH, Leics, England
关键词
D O I
10.1002/sim.861
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
A key tool for assessing the relative cost-effectiveness of two treatments in health economics is the incremental C/E acceptability curve. We present Bayesian computations for this curve in the case where data on both costs and efficacy are available from a clinical trial. Analysis is given under various formulations of prior information. A case study is analysed in which reasonable prior information is shown to strengthen substantially the posterior inference, leading to a more conclusive assessment of cost-effectiveness. Calculations can be performed using readily available Bayesian software. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:733 / 753
页数:21
相关论文
共 50 条
  • [41] BCEA: A R PACKAGE TO PERFORM BAYESIAN COST-EFFECTIVENESS ANALYSIS
    Baio, G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A550 - A550
  • [42] The performance of a Bayesian value-based sequential clinical trial design in the presence of an equivocal cost-effectiveness signal: evidence from the HERO trial
    Welch, Charlie
    Forster, Martin
    Ronaldson, Sarah
    Keding, Ada
    Corbacho-Martin, Belen
    Tharmanathan, Puvan
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2024, 24 (01)
  • [43] Bayesian sample size determination for cost-effectiveness studies with censored data
    Beavers, Daniel P.
    Stamey, James D.
    [J]. PLOS ONE, 2018, 13 (01):
  • [44] WILL COST-EFFECTIVENESS ANALYSIS WORSEN THE COST-EFFECTIVENESS OF CARE
    HIMMELSTEIN, DU
    WOOLHANDLER, S
    BOR, DH
    [J]. CLINICAL RESEARCH, 1987, 35 (03): : A744 - A744
  • [45] COST-EFFECTIVENESS ANALYSIS OF INTERVENTIONS THAT HAVE NOT SHOWN CLINICAL EFFECTIVENESS
    Teljeur, C.
    Harrington, P.
    O'Neill, M.
    Moran, P.
    Ryan, M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A751 - A751
  • [46] Cost-effectiveness of clopidogrel in Mexico: Within trial analysis
    Jerjes-Sanchez, C.
    Trujillo, A.
    Ramos, M. A.
    Hernandez, I
    Alvarado, R.
    Cruz, A.
    Rangel, F. J.
    Morales, E.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A344 - A344
  • [47] Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set
    Dakin, Helen
    Gray, Alastair
    Fitzpatrick, Ray
    MacLennan, Graeme
    Murray, David
    [J]. BMJ OPEN, 2012, 2 (01):
  • [48] A trial of the clinical and cost-effectiveness of a supervised exercise programme for claudication
    Lee, HLD
    Mehta, T
    Ray, B
    Heng, MST
    McCollum, PT
    Chetter, IC
    [J]. BRITISH JOURNAL OF SURGERY, 2005, 92 : 11 - 11
  • [49] Bayesian Hierarchical Models for Cost-Effectiveness Analyses that Use Data from Cluster Randomized Trials
    Grieve, Richard
    Nixon, Richard
    Thompson, Simon G.
    [J]. MEDICAL DECISION MAKING, 2010, 30 (02) : 163 - 175
  • [50] Missing data in trial-based cost-effectiveness analysis: the current state of play
    Noble, Sian Marie
    Hollingworth, William
    Tilling, Kate
    [J]. HEALTH ECONOMICS, 2012, 21 (02) : 187 - 200